ライフサイエンスコーパス: pneumococcal conjugate vaccine

1 No benefit was seen after pneumococcal conjugate vaccine.

2 protein-specific IgG responses to a soluble pneumococcal conjugate vaccine.

3 se with serotypes not covered by heptavalent pneumococcal conjugate vaccine.

4 effect was not observed using purified PS or pneumococcal conjugate vaccine.

5 fections since licensure of the seven-valent pneumococcal conjugate vaccine.

6 1% decrease), age-groups targeted to receive pneumococcal conjugate vaccine.

7 following a clinical trial of a seven-valent pneumococcal conjugate vaccine.

8 body responses of patients undergoing HCT to pneumococcal conjugate vaccine.

9 wi, in 2009-2011, before the introduction of pneumococcal conjugate vaccine.

10 was used to study the impact of the 7-valent pneumococcal conjugate vaccine.

11 ed to prevent, as has already been seen with pneumococcal conjugate vaccines.

12 as an immunogenic carrier protein in future pneumococcal conjugate vaccines.

13 valuation of immunization regimens involving pneumococcal conjugate vaccines.

14 , >75% being of serotypes covered by current pneumococcal conjugate vaccines.

15 Pneumococcal conjugate vaccine 10 (PCV10) and pneumococc

16 neumococcal conjugate vaccine 10 (PCV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in c

17 Serotypes in the 7-valent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F,

18 the 7 states had received at least 1 dose of pneumococcal conjugate vaccine; 43% of white and 39% of

19 e (HD) patients were immunized with 7-valent pneumococcal conjugate vaccine (7-OMPC) followed by one

20 rial colonization compared with the 7-valent pneumococcal conjugate vaccine (7vCRM) in young children

21 t publications found, most used the 7-valent pneumococcal conjugate vaccine (7vCRM).

22 nticapsular antibody responses to a 7-valent pneumococcal conjugate vaccine (7VPnC) were measured in

23 ctive interventions are available, including pneumococcal conjugate vaccine and case management.

24 es for China; and to consider the effects of pneumococcal conjugate vaccine and rotavirus vaccine in

25 More recent prevention measures such as the pneumococcal conjugate vaccine and universal screening o

26 against 12 serotypes contained in 13-valent pneumococcal conjugate vaccine, and evaluated determinan

27 o estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates.

28 V23 serotypes not contained in the 13-valent pneumococcal conjugate vaccine (AOR, 1.70; 95% CI, .30-9

29 PS- and protein-specific IgG responses to a pneumococcal conjugate vaccine are inhibited in ICOS(-/-

30 Pneumococcal conjugate vaccines are important for the pr

31 Pneumococcal conjugate vaccines are important tools in t

32 To understand and model the impact of pneumococcal conjugate vaccines at the population level,

33 ion of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 mo

34 lates were serotypes included in heptavalent pneumococcal conjugate vaccines currently being evaluate

35 m 769 children 2-30 months old in a 7-valent pneumococcal conjugate vaccine dosing trial.

36 rial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing v

37 ian visits in which impact was attributed to pneumococcal conjugate vaccines, either as efficacy or e

38 re immunized with either 2 doses of 7-valent pneumococcal conjugate vaccine followed by 1 dose of 23-

39 Introduction of pneumococcal conjugate vaccine for children could affect

40 Following recommendation of a new 7-valent pneumococcal conjugate vaccine for children in October 2

41 Pneumococcal conjugate vaccine for infants has recently

42 ensing, in February 2000, of the heptavalent pneumococcal conjugate vaccine for young children.

43 A 13-valent pneumococcal conjugate vaccine has been studied in adult

44 Pneumococcal conjugate vaccines have had unprecedented s

45 yte antigen A2 (arm A, n = 28) also received pneumococcal conjugate vaccine immunizations before and

46 Factors associated with pneumococcal conjugate vaccine immunogenicity have not b

47 sions occurred after the introduction of the pneumococcal conjugate vaccine in 2006: hospital admissi

48 following the introduction of the 13-valent pneumococcal conjugate vaccine in 2011.

49 upport recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-

50 e nonvaccine serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2

51 nce supporting the beneficial effects of the pneumococcal conjugate vaccines in children.

52 ed to perform a protective efficacy trail of pneumococcal conjugate vaccines in infants, among whom m

53 ublicly purchased meningococcal conjugate or pneumococcal conjugate vaccines in the private sector in

54 tes were not contained in PCV7 (the 7-valent pneumococcal conjugate vaccine), including 1 isolate tha

55 luded in the previously recommended 7-valent pneumococcal conjugate vaccine, including serotype 19A,

56 In response to the selective pressure of pneumococcal conjugate vaccine, increased asymptomatic c

57 roup 6 pneumococci, and investigated whether pneumococcal conjugate vaccine-induced serotype 6A and 6

58 Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants i

59 The multivalent pneumococcal conjugate vaccine is effective against both

60 The multivalent pneumococcal conjugate vaccine is effective against both

61 istance with the introduction of heptavalent pneumococcal conjugate vaccine is likely to be partially

62 Pneumococcal conjugate vaccine is not only effective aga

63 The use of the pneumococcal conjugate vaccine is preventing disease in

64 niversal immunization of young children with pneumococcal conjugate vaccine, it is unclear whether th

65 Much of the efficacy of current pneumococcal conjugate vaccines lies in their ability to

66 ate vaccine, the recently licensed 13-valent pneumococcal conjugate vaccine may reduce the incidence

67 The introduction of pneumococcal conjugate vaccines necessitates continued m

68 y was to analyse the effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal

69 tine childhood vaccination using heptavalent pneumococcal conjugate vaccine, one concern has been the

70 cyte antigen A2 (arm B, n = 26) received the pneumococcal conjugate vaccine only.

71 tion of routine vaccination with heptavalent pneumococcal conjugate vaccine, overall invasive pneumoc

72 eplacement disease following introduction of pneumococcal conjugate vaccine (PCV) are attributable to

73 In contrast, among children immunized with pneumococcal conjugate vaccine (PCV) both before and aft

74 Immunization schedules with pneumococcal conjugate vaccine (PCV) differ among countr

75 approximately 30%-60% of episodes before the pneumococcal conjugate vaccine (PCV) era.

76 We investigated the impact of infant pneumococcal conjugate vaccine (PCV) immunization on pne

77 The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countr

78 dle-income countries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting again

79 Pneumococcal conjugate vaccine (PCV) is now recommended

80 e aimed to determine the effect of 13-valent pneumococcal conjugate vaccine (PCV) on colonization.

81 Pneumococcal conjugate vaccine (PCV) was introduced into

82 ined whether revaccination with the 7-valent pneumococcal conjugate vaccine (PCV) would enhance these

83 ccal empyema (PPE) prior to licensure of the pneumococcal conjugate vaccine (PCV-7) in 2000.

84 cine group), all residents received 7-valent pneumococcal conjugate vaccine (PCV-7), while in another

85 ccal polysaccharide vaccine (PPV; n = 14) or pneumococcal conjugate vaccine (PCV; n = 11).

86 Pneumococci could evade pneumococcal conjugate vaccines (PCV) by modifying, muta

87 The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly red

88 March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licens

89 Both the 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) induce

90 evaluating the immune response to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4

91 ults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first epi

92 Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four us

93 recommend a combined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-va

94 llogeneic HSCT received 3 doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month interv

95 V-Hib) at 2, 3, and 4 months of age, and the pneumococcal conjugate vaccine (PCV13) at 2, 4, and 12 m

96 The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population

97 The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) compared with 23-

98 The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been

99 ugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010.

100 d the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) in this populatio

101 commenced the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine

102 In France, the switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13) occurred in June

103 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal m

104 are available on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal o

105 The 13-valent pneumococcal conjugate vaccine (PCV13) protects against

106 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-vale

107 In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

108 In March 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seve

109 dual serotypes, one or both isolates were a pneumococcal conjugate vaccine (PCV13) serotype.

110 The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to i

111 Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was inferred befo

112 In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to

113 .9% (12/43) (P = 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

114 A second-generation 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and

115 In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and

116 The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to r

117 (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently repo

118 In 2012/2013, a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended f

119 Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity inc

120 n (UAD) assay capable of detecting 13-valent pneumococcal conjugate vaccine (PCV13)-associated seroty

121 aused by serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13).

122 s before and after the widespread use of the pneumococcal conjugate vaccine PCV7.

123 tality during baseline (2000-2007), 7-valent pneumococcal conjugate vaccine (PCV7) (2008-2010), and P

124 Serotypes associated with 7-valent pneumococcal conjugate vaccine (PCV7) accounted for 25%

125 (PCV13) was licensed to replace the 7-valent pneumococcal conjugate vaccine (PCV7) based on serologic

126 outine infant immunisation with seven-valent pneumococcal conjugate vaccine (PCV7) began in the USA i

127 The introduction of heptavalent pneumococcal conjugate vaccine (PCV7) could reduce acqui

128 2001, a serious shortage of the heptavalent pneumococcal conjugate vaccine (PCV7) developed in 34 st

129 Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replace

130 Use of heptavalent protein-polysaccharide pneumococcal conjugate vaccine (PCV7) has been associate

131 Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) has led to signifi

132 Vaccination with heptavalent pneumococcal conjugate vaccine (PCV7) has significantly

133 in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-v

134 Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced ma

135 he introduction of the pediatric heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its e

136 Since the pediatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence

137 he US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

138 Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at

139 South Africa introduced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 usin

140 The introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in September 2006

141 tantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immu

142 The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. chil

143 imed to determine the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumo

144 characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal ca

145 from serotype 6A, the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on the carriage of

146 Widespread use of pneumococcal conjugate vaccine (PCV7) resulted in decrea

147 Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other th

148 ndividual serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) transmitted by the

149 en in Israel who were enrolled in a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

150 nce were evaluated after 7 years of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children

151 We assessed the impact of 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococca

152 In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in

153 In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in

154 A heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in 20

155 e following the introduction of seven-valent pneumococcal conjugate vaccine (PCV7) were associated wi

156 and and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent

157 hether donor immunization with a heptavalent pneumococcal conjugate vaccine (PCV7) would elicit prote

158 Before the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumoco

159 onses induced by a 7-valent, polysaccharide, pneumococcal conjugate vaccine (PCV7).

160 allenge, even after introduction of 7-valent pneumococcal conjugate vaccine (PCV7).

161 monia (CAP) after implementation of 7-valent pneumococcal conjugate vaccine (PCV7).

162 rriage after 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infanc

163 The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respect

164 whether introduction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respect

165 ) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).

166 The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the

167 Indirect effects of pediatric use of pneumococcal conjugate vaccines (PCVs) affect rates of a

168 Pneumococcal conjugate vaccines (PCVs) are being used wo

169 Pneumococcal conjugate vaccines (PCVs) are highly effect

170 Pneumococcal conjugate vaccines (PCVs) are used in many

171 hildhood death, even though highly effective pneumococcal conjugate vaccines (PCVs) are used in natio

172 Pneumococcal conjugate vaccines (PCVs) have been introdu

173 Pneumococcal conjugate vaccines (PCVs) have demonstrated

174 titis media (OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded pre

175 Pneumococcal conjugate vaccines (PCVs) have substantiall

176 Pneumococcal conjugate vaccines (PCVs) have substantiall

177 The use of pneumococcal conjugate vaccines (PCVs) in children has a

178 neumonia associated with the introduction of pneumococcal conjugate vaccines (PCVs) in five countries

179 information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income cou

180 Use of pneumococcal conjugate vaccines (PCVs) in resource-poor

181 Pneumococcal conjugate vaccines (PCVs) prevent vaccine s

182 Pneumococcal conjugate vaccines (PCVs) target only a few

183 of IPD, and trends after the introduction of pneumococcal conjugate vaccines (PCVs).

184 Pneumococcal conjugated vaccines (PCVs) impact on comple

185 Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluat

186 nts in Soweto, South Africa, that a 9-valent pneumococcal conjugate vaccine, PncCV, prevents 31% (95%

187 of age received 2, 3, or 4 doses of 7-valent pneumococcal conjugate vaccine (PnCRM7) or control vacci

188 Despite the success of the pneumococcal conjugate vaccine, pneumococcal pneumonia r

189 The seven-valent pneumococcal conjugate vaccine prevents invasive disease

190 Finally, the commercial pneumococcal conjugate vaccine, Prevnar, contained a TLR

191 The 7-valent pneumococcal conjugate vaccine protected HIV-infected ad

192 Routine immunization with pneumococcal conjugate vaccines should substantially red

193 The development and licensing of pneumococcal conjugate vaccines that are safe and effect

194 were immunized with 1 of the 3 experimental pneumococcal conjugate vaccines that contain 6B and 19F

195 ld be disrupted by vaccinating children with pneumococcal conjugate vaccines that reduced nasopharyng

196 occal serotypes not included in the 7-valent pneumococcal conjugate vaccine, the emergence of a drug-

197 Finally, in the era of the pneumococcal conjugate vaccine, the frequency of rrgC in

198 efore and after introduction of the 7-valent pneumococcal conjugate vaccine, the recently licensed 13

199 cross-reactive antibodies are elicited with pneumococcal conjugate vaccines, the memory cells for lo

200 Following introduction of the 7-valent pneumococcal conjugate vaccine to the United States, rat

201 We reanalyzed the 7-valent pneumococcal conjugate vaccine trial FinOM for preventio

202 he scenarios considered suggest that ceasing pneumococcal conjugate vaccine use would cause an increa

203 e immunogenicity of experimental multivalent pneumococcal conjugate vaccines varies with different po

204 When seven-valent pneumococcal conjugate vaccine was introduced in the USA

205 Pneumococcal conjugate vaccines will eventually be licen

206 Since the introduction of the pneumococcal conjugate vaccines with/without protein D o